What is it? Why is it important?

Clinical studies vary greatly in scope, complexity, and budget. Identifying Critical-to-Quality (CtoQ) factors, and the risks associated with these factors, are crucial to:

  • Ensure efficiency by focusing on risks that are critical to achieving study objectives (i.e. study outcome/endpoint)
  • Provide credible and scientifically valuable research results

 

Protecting the integrity of study quality factors is essential to:

  • Protect study participants (e.g. participant rights and safety)
  • Have reliable and interpretable study results
  • Have confidence in ensuing study interpretation and decision(s) taken (e.g. publishing)

 

Once CtoQ factors are identified, risks that threaten their integrity are determined and decisions are taken whether to accept or mitigate risks (i.e. based on risk probability, detectability and impact).

 

As research progresses, investigational product (IMP / IMD) uncertainties may increase (e.g. safety, efficacy). Therefore, product knowledge during its development, requires that CtoQ factors and risks threatening their integrity must be identified and assessed on a continuous basis.

What do I need to do?

As a SP-INV during study design development:

  • Seek input from a broad range of stakeholders (e.g. study population representatives, data manager, statistician)
  • Identify and prioritize quality factors that are critical to the study (i.e. in the Monitoring Plan focus on aspects that are CtoQ)
  • Identify risks threatening the integrity of CtoQ factors
  • Implement risk control-measures that are proportionate to inherent risks, and the importance of the collected information
  • Train applicable study staff on study identified CtoQ factors, risks threatening their integrity, and any planned risk control-measures

 

As a SP-INV, plan and define for study conduct how to:

  • Monitor the integrity of CtoQ factors
  • Control risks to CtoQ factors (i.e. control-measure adjustments may become necessary or new / unanticipated risks may arise)
  • Aassess the efficacy and applicability of risk control-measures
  • Retain oversight and document CtoQ management

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • 3.11.4.3 Monitoring plan and CtoQ
  • 6.2 Factors critical to quality
  • 7.3 Management of CtoQ factors

ICH E8(R1) – see in particular guidelines

  • 3. Designing quality into clinical studies
  • 3.1 Quality by design of clinical studies
  • 3.2 Critical to quality factors
  • 3.3 Approach to identify CtoQ factors
Abbreviations
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • IMD – Investigational Medical Device
  • IMP – Investigational Medicinal Product
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Quality Management System (QMS) ↦ Critical to Quality
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Quality Management System (QMS) ↦ Critical to Quality